FDA Approves Wilserdly (giredestrant) for ER-Positive, ESR1-Mutated Advanced Breast Cancer

Nov 17, 2026 - 02:00
 0  0
South San Francisco, CA -- November 16, 2026 -- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Wilserdly (giredestrant) in...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0